Company: CRVO
Filing Date: 2025-10-29
Form Type: 8-K
Source: 0001437749-25-032184
Chunk: 0

Company: CervoMed Inc.
Filing Date: 2025-10-29
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On October 27, 2025, the Board of Directors (the “ Board”) of CervoMed Inc. (the “ Company”) appointed David Quigley as a director of the Company.

Mr. Quigley, age 58, served at the global consulting firm McKinsey & Company (“ McKinsey”) for more than 25 years, including as Senior Partner from 2010 to 2025. While a Senior Partner at McKinsey, Mr. Quigley at times held various leadership roles including Global Head of Private Capital (Private Equity), North America Head of Life Sciences, and Global Lead of Life Sciences Commercial. He also served as a guest lecturer on Life Sciences at Columbia University’s Mailman School of Public Health from 2010 to 2017. Mr. Quigley holds a B. A. from University College Dublin, an M. Sc. from Queen’s University Belfast, and an M. B. A. from INSEAD.

In connection with his appointment to the Board, Mr. Quigley was granted a stock option to purchase 16,200 shares of the Company’s common stock. The option grant has an exercise price equal to $7.02, the closing price of the Company’s common stock on the grant date, will vest in 36 equal monthly installments on the last calendar day of each month commencing October 31, 2025, and will be subject to the other terms and conditions set forth in the Company’s 2025 Equity Incentive Plan and its standard form of option award agreement. In addition to the option grant, (i) Mr. Quigley will receive the other cash and equity compensation payable to the Company’s non-employee directors pursuant to its non-employee director compensation program (pro-rated as applicable to reflect the actual time Mr. Quigley will serve on the Board for this year) and (ii) effective upon his election to the Board, the Company and Mr. Quigley entered into the Company’s standard form of director and officer indemnification agreement.

Effective upon Mr. Quigley’s election as a director of the Company, the size of the Board was expanded from seven to eight members and Mr. Quigley will serve for a term to continue until the Company’s next annual meeting of stockholders. Mr. Quigley will not serve